Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

High Incidence of TP53 and Epigenetic Modifying Oncogenes Mutations in a Large Cohort of Patients Enrolled in Phase 1 Clinical Trials for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Cyril Quivoron, PhD, Jean-Marie Michot, MD, Valérie Camara-clayette, PhD, Alina Danu, MD, Julien Lazarovici, MD, Clementine Sarkozy, MD PhD, David Ghez, MD PhD, Julien Rossignol, MD PhD, Capucine Baldini, MD, Patricia Martin-Romano, MD PhD, Helene Lecourt, Veronique Vergé, MD, Andrea Varga, MD, Sophie Cotteret, MD PhD, Peggy Dartigues-Cuillères, MD, Christophe Massard, MD PhD, Vincent Ribrag, MD

Blood (2020) 136 (Supplement 1): 10–11.

https://doi.org/10.1182/blood-2020-136114

Published: 2020

Journal Articles

Real Time Pathological and Molecular Characterization of Aggressive B-Cell Lymphomas Based on a National Network. a Lysa Project

Christiane Copie Bergman, MDPhD, Elodie Bohers, PhD, Peggy Dartigues-Cuillères, MD, Pierre-Julien Viailly, Philippe Ruminy, PhD, Vinciane Marchand, Marie-Helene Delfau-Larue, Corinne Haioun, MDPhD, Cyrielle Robe, Elsa Poullot, MD, Steven Le Gouill, MD PhD, Yannick Le Bris, PharmD, Céline Bossard, MD, Anne Moreau, MD, Vincent Ribrag, MD, Valérie Camara-clayette, PhD, Cyril Quivoron, PhD, Gilles Salles, MDPhD, Sophie Cotteret, MD PhD, Pierre Sujobert, MD PhD, Alexandra Traverse-Glehen, MD PhD, Claire Mauduit, Pascaline Etancelin, Sarah Huet, Liana Veresezan, MD, Krimo Bouabdallah, MD, Marie Parrens, MD, Audrey Gros, PhD, Samuel Amintas, David Sibon, MD PhD, Ludovic Lhermitte, MD PhD, Thomas Steimle, Sophie Kaltenbach, Bettina Fabiani, MD, Camille Laurent, MD PhD, Barbara Burroni, Laurent Martin, MD PhD, Thierry Jo Molina, MDPhD, Lysa LYSARC study group, Fabrice Jardin, MD PhD

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-141953

Published: 2020

Journal Articles

Is Molecular Characterization Useful for Targeted Therapy Orientation in Patients with Relapsed or Refractory DLBCL Included in Early Phase Clinical Trials?

Jean-Marie Michot, MD, Valérie Camara-Clayette, PhD, Cyril Quivoron, PhD, Alina Danu, MD, Julien Lazarovici, MD, David Ghez, MD PhD, Julien Rossignol, MD PhD, Capucine Baldini, MD, Patricia Martin-Romano, MD PhD, Clementine Sarkozy, MD PhD, Andrea Varga, MD, Helene Lecourt, Veronique Vergé, MD, Sophie Cotteret, MD PhD, Peggy Dartigues-Cuillères, MD, Christophe Massard, MD PhD, Vincent Ribrag, MD

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-136134

Published: 2020

Journal Articles

Comparative Study of Tumor Biopsy and Ctdna to Support Patient Selection in Phase I Trials: The Gustave Roussy Single Center Experience in Aggressive B-Cell Lymphomas

Anthony Tarabay, MD, Jean-Marie Michot, MD, Anne Aupérin, Julien Lazarovici, Julien Rossignol, MD PhD, David Ghez, MD PhD, Peggy Dartigues-Cuillères, MD, Veronique Vergé, Vincent Ribrag, MD, Christophe Massard, Valérie Camara-clayette

Blood (2019) 134 (Supplement_1): 1496.

https://doi.org/10.1182/blood-2019-127170

Published: 2019

Journal Articles

Feasibility and Benefit of Molecularly-Informed Enrollment into Early Phase Clinical Trials for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Blood (2018) 132 (Supplement 1): 4110.

https://doi.org/10.1182/blood-2018-99-110852

Published: 2018

Journal Articles

Pan-HDAC Inhibitors May Restore PRDM1 Expression in Follicular Lymphoma

Thierry Fest, Fabienne Desmots-Loyer, Mikael Roussel, MD PhD, Celine Pangault, PhD, Cedric Pastoret, MD, Francisco Llamas-Gutierrez, Eric Guiheneuf, Valérie Camara-clayette, Thierry Lamy, Pr, MD PhD, Karin Tarte, PhD, Vincent Ribrag, MD

Blood (2018) 132 (Supplement 1): 2848.

https://doi.org/10.1182/blood-2018-99-113269

Published: 2018

Journal Articles

Perinucleolar relocalization and nucleolin as crucial events in the transcriptional activation of key genes in mantle cell lymphoma

Jeanne Allinne, Andrei Pichugin, Olga Iarovaia, Manel Klibi, Ana Barat, Ewa Zlotek-Zlotkiewicz, Diana Markozashvili, Natalia Petrova, Valérie Camara-Clayette, Elena Ioudinkova, Joëlle Wiels, Sergey V. Razin, Vincent Ribrag, Marc Lipinski, Yegor S. Vassetzky

Blood (2014) 123 (13): 2044–2053.

https://doi.org/10.1182/blood-2013-06-510511

Published: 2014

Includes: Supplemental data

Journal Articles

Phase 1b Study Of Everolimus (RAD001), a mTORC1 Inhibitor In Combination With Rituximab (R), In Patients With Relapsed Or Refractory Indolent CD20+ Lymphomas Or Transformed Aggressive CD20+ Lymphomas

Vincent Ribrag, Lionel Karlin, MD, Louis Terriou, MD, Thomas Gastinne, MD, Valérie Camara-Clayette, Ph.D, Steven Le Gouill, MD, PhD, Franck Morschhauser, MD, PhD, Herve Tilly, MD, Bertrand Coiffier, MD, PhD

Blood (2013) 122 (21): 5128.

https://doi.org/10.1182/blood.V122.21.5128.5128

Published: 2013

Journal Articles

Down-regulation of the RUNX1-target gene NR4A3 contributes to hematopoiesis deregulation in familial platelet disorder/acute myelogenous leukemia

Dominique Bluteau, Laure Gilles, Morgane Hilpert, Iléana Antony-Debré, Chloe James, Najet Debili, Valerie Camara-Clayette, Orianne Wagner-Ballon, Veronique Cordette-Lagarde, Thomas Robert, Hugues Ripoche, Patrick Gonin, Sabina Swierczek, Josef Prchal, William Vainchenker, Remi Favier, Hana Raslova

Blood (2011) 118 (24): 6310–6320.

https://doi.org/10.1182/blood-2010-12-325555

Published: 2011

Includes: Supplemental data

Journal Articles

Implication of BMP7 in Human Mantle Cell Lymphoma (MCL) Secondary Drug Resistance.

Valerie Camara-Clayette, PhD, Serge Koscielny, PhD, Thierry Lamy, MD, PhD, Thierry Fest, MD, Marc Bernard, MD, Vincent Ribrag, MD

Blood (2006) 108 (11): 2589.

https://doi.org/10.1182/blood.V108.11.2589.2589

Published: 2006

Journal Articles

Canonical NF-kB Pathway Is Not Constitutively Activated and May Not Be the Major Bortezomib Target in Mantle Cell Lymphoma (MCL).

Valerie Camara-Clayette, PhD, Yves Lepelletier, phD, Ivan Moura, phD, William Vainchenker, MD, phD, Olivier Hermine, MD, phD, Vincent Ribrag, MD

Blood (2006) 108 (11): 2591.

https://doi.org/10.1182/blood.V108.11.2591.2591

Published: 2006

Journal Articles

JNK Pathway Is Constitutively Activated and Is Required for Survival in Human Mantle-Cell Lymphoma Fresh Cells and Cell-Lines.

Valerie Camara-Clayette, PhD, William Vainchenker, MD, phD, Serge Koscielny, phD, Olivier Hermine, MD, phD, Vincent Ribrag, MD

Blood (2006) 108 (11): 4602.

https://doi.org/10.1182/blood.V108.11.4602.4602

Published: 2006

NARROW

High Incidence of TP53 and Epigenetic Modifying Oncogenes Mutations in a Large Cohort of Patients Enrolled in Phase 1 Clinical Trials for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Real Time Pathological and Molecular Characterization of Aggressive B-Cell Lymphomas Based on a National Network. a Lysa Project

Is Molecular Characterization Useful for Targeted Therapy Orientation in Patients with Relapsed or Refractory DLBCL Included in Early Phase Clinical Trials?

Comparative Study of Tumor Biopsy and Ctdna to Support Patient Selection in Phase I Trials: The Gustave Roussy Single Center Experience in Aggressive B-Cell Lymphomas

Feasibility and Benefit of Molecularly-Informed Enrollment into Early Phase Clinical Trials for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Pan-HDAC Inhibitors May Restore PRDM1 Expression in Follicular Lymphoma

Perinucleolar relocalization and nucleolin as crucial events in the transcriptional activation of key genes in mantle cell lymphoma

Phase 1b Study Of Everolimus (RAD001), a mTORC1 Inhibitor In Combination With Rituximab (R), In Patients With Relapsed Or Refractory Indolent CD20+ Lymphomas Or Transformed Aggressive CD20+ Lymphomas

Down-regulation of the RUNX1-target gene NR4A3 contributes to hematopoiesis deregulation in familial platelet disorder/acute myelogenous leukemia

Implication of BMP7 in Human Mantle Cell Lymphoma (MCL) Secondary Drug Resistance.

Canonical NF-kB Pathway Is Not Constitutively Activated and May Not Be the Major Bortezomib Target in Mantle Cell Lymphoma (MCL).

JNK Pathway Is Constitutively Activated and Is Required for Survival in Human Mantle-Cell Lymphoma Fresh Cells and Cell-Lines.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only